Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
NCT03025867
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Recurrent Ovarian Cancer
Interventions
DRUG:
Niraparib
Sponsor
Tesaro, Inc.